A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON (PALO) FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MALIGNANT GLIOMA (MG) PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB
Publication
, Conference
Affronti, ML; Brickhouse, A; Marcello, J; Herndon, J; Reardon, DA; Desjardins, A; Vredenburgh, JJ
Published in: NEURO-ONCOLOGY
October 1, 2009
Duke Scholars
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
October 1, 2009
Volume
11
Issue
5
Start / End Page
656 / 656
Location
New Orleans, LA
Publisher
DUKE UNIV PRESS
Conference Name
Joint Meeting of the Society-forNeuro-Oncology/American-Association-of-Neurological -Surgeons/Congress of Neurological Surgeons
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Affronti, M. L., Brickhouse, A., Marcello, J., Herndon, J., Reardon, D. A., Desjardins, A., & Vredenburgh, J. J. (2009). A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON (PALO) FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MALIGNANT GLIOMA (MG) PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB. In NEURO-ONCOLOGY (Vol. 11, pp. 656–656). New Orleans, LA: DUKE UNIV PRESS.
Affronti, Mary Lou, Alise Brickhouse, Jennifer Marcello, James Herndon, David A. Reardon, Annick Desjardins, and James J. Vredenburgh. “A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON (PALO) FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MALIGNANT GLIOMA (MG) PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB.” In NEURO-ONCOLOGY, 11:656–656. DUKE UNIV PRESS, 2009.
Affronti ML, Brickhouse A, Marcello J, Herndon J, Reardon DA, Desjardins A, et al. A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON (PALO) FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MALIGNANT GLIOMA (MG) PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB. In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2009. p. 656–656.
Affronti, Mary Lou, et al. “A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON (PALO) FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MALIGNANT GLIOMA (MG) PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB.” NEURO-ONCOLOGY, vol. 11, no. 5, DUKE UNIV PRESS, 2009, pp. 656–656.
Affronti ML, Brickhouse A, Marcello J, Herndon J, Reardon DA, Desjardins A, Vredenburgh JJ. A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON (PALO) FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MALIGNANT GLIOMA (MG) PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB. NEURO-ONCOLOGY. DUKE UNIV PRESS; 2009. p. 656–656.
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
October 1, 2009
Volume
11
Issue
5
Start / End Page
656 / 656
Location
New Orleans, LA
Publisher
DUKE UNIV PRESS
Conference Name
Joint Meeting of the Society-forNeuro-Oncology/American-Association-of-Neurological -Surgeons/Congress of Neurological Surgeons
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences